Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07015528 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessment of Drug Liking In Peri-procedural Clinical Settings

StatusEnrolling by Invitation
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Aug 31, 2026 → Dec 31, 2026
See other at-risk trials from Stanford University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Aug 31, 2026 to Dec 31, 2026
    • Study completion pushed from Aug 31, 2027 to Sep 30, 2027
    • Eligibility criteria expanded, about 29 words
    • Secondary endpoints: details revised at 1 of 2 entries
  2. Enrollment target: 100 to 130
    • Primary completion date: Jul 31, 2026 to Aug 31, 2026
    • Study completion date: Jul 31, 2027 to Aug 31, 2027
    • Eligibility criteria expanded, about 58 words
    v5
  3. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Sep 1, 2025 to Sep 30, 2025
    v4
  4. Start date: Jul 31, 2025 to Sep 1, 2025
    • Eligibility criteria shortened, about 3 words
    v3
  5. Start date: Jun 2025 to Jul 31, 2025v2 Show 6 more changesShow less
    • Primary completion date: Jun 2026 to Jul 31, 2026
    • Study completion date: Jun 2027 to Jul 31, 2027
    • Interventions: Anti-dopaminergic Medication (Drug), Placebo (Drug) to Droperidol (Drug), Placebo (Drug)
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints expanded, about 7 words
    • Study description expanded, about 60 words
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate whether medications used in peri-procedural clinical settings can modulate drug liking.
Trial Details
NCT Number NCT07015528
Lead Sponsor Stanford University
Conditions
(from sponsor)		 Drug Liking
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov